SOURCE: CLX Investment Company, Inc.

March 11, 2008 11:40 ET

CLX Investment Company Announces Selection of Contract Research Organization (CRO) for Clinical Trials on Zonda's Rapid Point of Care Test for Chlamydia

MURRIETA, CA--(Marketwire - March 11, 2008) - CLX Investment Company, Inc. (OTCBB: CLXN), which owns 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, today announced that the company has selected Trial Care International, LLC (TCI) to serve as Contract Research Organization (CRO) for the clinical trials for Zonda's rapid point of care test for chlamydia.

Trial Care International, LLC ( specializes in the management of Phase I-IV clinical trials in a wide range of therapeutic areas and provides clinical management, monitoring, auditing and regulatory services to the pharmaceutical and biotech industry through partnering and long-term relationships with its clients.

TCI offers a full range of clinical services specializing in: protocol design, project management, investigator recruitment and selection, document collection and supply shipping, contract and grant administration, investigator meeting coordination and facilitation, monitoring, GCP auditing and regulatory consulting.

Safis Solutions assisted with selection of Trial Care International through a process that began with a request for proposal from several CROs. Two finalists were then identified to make detailed presentations, and TCI was ultimately selected.

Safis Solutions (, an Indianapolis-based regulatory compliance consulting company serving pharmaceutical, medical device and biotech companies worldwide, has been retained as a sub-contractor of American Health Partners, LLC (AHP), which has been engaged by CLX to assist with the launch of medical diagnostic testing products in its subsidiary operations. Safis Solutions is providing ongoing consulting services in the areas of regulatory approvals and quality systems for Zonda and additional potential future medical diagnostic technologies acquired by CLX.

"We are pleased to have identified Trial Care International as the CRO for Zonda's clinical trials and look forward to their support and expertise. Having the services of a top quality CRO is a crucial element in clinical trial management. This is a big step forward in the process of bringing this important product to the market. We believe Trial Care International is the ideal partner to assist us as we navigate this process," stated Vera Leonard, chief executive officer of Zonda and CLX.

Ms. Leonard recently participated in a question and answer feature that has been posted to the CLX website at, and a link to the interview has also been added to the company's profile on the home page of Equity Digest at

The question and answer feature includes a detailed discussion by Ms. Leonard of the estimated market potential for Zonda's rapid point of care diagnostic test for chlamydia.

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit

About CLX Investment Company

CLX Investment Company ( holds a 51% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (, a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contacts:
    For CLX Investment Company:
    Gemini Financial Communications
    A. Beyer
    Email Contact